References
- Fogarty PF. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hem Oncol Clin North Am. 2009;23:1213–21.
- Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al.. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.
- Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al.. Dexamethasone plus rituximab yields higher sustained response rates tan dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115:2755–62.
- Li Z, Mou W, Lu G, Cao J, He X, Pan X, et al.. Low dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93:91–8.
- Dierickx D, Delannoy D, Saja K, Verhoef G, Provan D. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am J Hematol. 2011;86:278–91.
- Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol. 1993;84:542–4.
- MIlani C, Castillo J. Veltuzumab, an anti-CD20 mAB for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009;11:200–7.
- Gómez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, et al.. Low dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116:4783–5.
- Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al.. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25–33.
- Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, et al.. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112:999–1004.
- Zaja F, Battista ML, Pirrota MT, Palmieri S, Montagna M, Vianelli N, et al.. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93:930–3.
- Marsh JC, Gordon-Smith EC. CAMPATH 1H in the treatment of autoimmune cytopenias. Cytotherapy. 2011;3:189–95.